Premier Health Brings Another International Cancer Study to the Dayton Region

DAYTON, Ohio (August 18, 2025) – Premier Health’s Miami Valley Hospital South led the way as the first of 23 international sites to open enrollment for a new clinical trial focused on advanced ovarian and related cancers. The study gives eligible patients access to an investigational drug combination currently being studied for its potential to slow cancer growth when other treatments have stopped working.

The trial, known as the BELLA study, is sponsored by Corcept Therapeutics with support from Syneos Health. It is testing an investigational oral medication called relacorilant, which is designed to block certain hormone signals that may cause cancer to resist chemotherapy. In this study, relacorilant is being combined with two existing cancer medications:

• Nab-paclitaxel (Abraxane), a chemotherapy drug that attacks rapidly dividing cancer cells
• Bevacizumab (Avastin), a targeted therapy that reduces the blood supply tumors need to grow

“Being the first site in the world to begin patient enrollment is a reflection of Premier Health’s clinical capabilities and commitment to expanding treatment options for patients facing difficult diagnoses,” says Michael Guy, MD, principal investigator for the study at Miami Valley Hospital South. He is joined on the research team by Thomas Reid, MD, and Juliet Wolford, MD.

The study is open to adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has returned or progressed after platinum-based chemotherapy and who meet other eligibility criteria. This condition is known as platinum-resistant disease, and treatment options are often limited.

Patients who qualify for the trial will receive a combination of oral and IV medications during monthly treatment cycles. The goal is to learn whether relacorilant can enhance the effects of chemotherapy and targeted therapy by making cancer cells more responsive to treatment. Participants will be closely monitored through regular clinic visits, blood tests, and scans.

“Offering this trial in the region allows patients to take part in research that explores potential new treatment approaches close to home,” says Guy. “It also contributes to a larger effort to develop more effective therapies for women facing these aggressive cancers.”

This research is part of Premier Health’s Office of Clinical Trials, which connects patients with cutting-edge studies and supports physicians in advancing care. All participants will complete an informed consent process before enrolling in the study, as required by federal research guidelines.

To learn more about the BELLA study or to ask about eligibility, contact Premier Health’s Office of Clinical Trials at (937) 915-2515 or email clinicaltrials@premierhealth.com. More information can also be found at ClinicalTrials.gov using the study ID: NCT06906341.

Contact Us

Discover more about Premier Health and join us in building healthier communities in Southwest Ohio. Learn more about working at Premier Health, becoming a volunteer, and making a gift to support our mission.